Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

The top events in Kenan Stadium from the last 10 decades
As the centennial season of Kenan Stadium approaches, the sun has risen and set on a plethora of memorable events held inside its walls. Despite...
Wed Aug 26, 2026

Live from Ireland: Festivities begin in Dublin
UNC leaders, student-athletes, fans, and alumni are arriving in Ireland ahead of the Tar Heels’ football season opener against Texas Christian University as part of...
Tue Aug 25, 2026

UNC move-in photo from the past stirs up big emotions, especially for parents
August brings the annual ritual of college freshmen leaving home to move into college dorms. Digging through the archives, I was struck by this 1997...
Tue Aug 25, 2026

To UNC's Freshmen — Trust Your Gut
You may or may not know your major. You may or may not stick with your original choice of study. A freshman at Stanford joined...
Sun Aug 23, 2026